alioua
08 Jun 2015
Re: Placing and share price i have also following this one and see the ceo present a few times always very impressive- the one reason i can see for the share not moving is that it is not yet in profit
nk1999
08 Jun 2015
Fund Managers "Woodford sees gains on the HorizonCitywire AA-rated equity manager Neil Woodford, the most respected UK investor of his generation, has snapped up more than 10% of biotech business Horizon Discovery (HZDN) via a share issue.Woodford has taken up an 11% stake in the business worth £19.1 million at a share price of 181.5p. Horizon listed at 180p in March last year.Now 10 years old, Horizon Discovery is a second-tier play on the recent biotech boom, providing genetic sequencing and profiling services to other business involved in primary research.The company was ranked as the fastest growing UK biotech business by Deloitte in 2013. Broker Peel Hunt this month reiterated its ‘buy’ recommendation on the business with a 270p price target while Panmure Gordon last month also confirmed its ‘buy’ rating on a target of 270p.The share issue, which was also supported by Woodford’s former employer Invesco Perpetual, raised £20 million in order to fund further growth."From Citywire.
claude reins
22 May 2015
Placing and share price The placing approved by the AGM based on my arithmetic dilutes the share price by around 14% but there has been little or no movement. Also, it seems that the joint Woodford / Invesco team have taken up their share and supported the placing at 190p. Anyone any thoughts on why the share price has not moved significantly, and whether we can expect it to dip gradually by that 14% in the next few weeks, when others cotton on to what is happening?On the basis of my calculations I have to grade it a sell until things realistically settle down.
claude reins
15 Apr 2015
Re: TV interview with CEO Don't understand it scientifically but sounds good logically. Key aspects of course in niche markets is how good is this company against competitors, if any, and also the value added placed by user drug companies and health organizations on their services.One of Small Company Sharewatch NAPs for this year, currently standing at around 2% down versus recommended buy price.
Dino78
14 Apr 2015
TV interview with CEO Morning all. We have just posted two short interviews (2mins each) we did with CEO Dr Darrin Disley. One is a general overview, the other based on today's results. You can watch both at the link below. I would welcome your feedback!!www.fmp-tv.co.uk/companies/horizon
KayCatso
18 Feb 2015
RNS re Funding grant for research Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M Innovate UK FundingConsortium to receive funding to develop enhanced biomanufacturing platformsbased on the Company's CHO cell line and gene editing platform Cambridge, UK, 18th February 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, announced today that together with the Centre for Process Innovation (CPI), a UK-based technology innovation center and part of the High Value Manufacturing Catapult, and Prof. Alan Dickson, Faculty of Life Sciences, University of Manchester, they have been selected to receive a funding award of £1.67M (approximately $2.56M USD). The Biotechnology and Biological Sciences Research Council (BBSRC) will provide £422K in funding, and the remainder will be from the UK's innovation agency, Innovate UK. Horizon will receive up to £747,000 (approximately $1,146,000 USD) which will be deployed within research performed in its Bioproduction business. The funding is awarded under Innovate UK's new 'Industrial Biotechnology Catalyst' scheme. This funding will support the development of a commercially valuable enhancement to Chinese Hamster Ovary (CHO) cell lines, critical tools for biomanufacturing of high value biopharmaceuticals. The project aims to develop a suite of engineered CHO cell lines containing a range of modifications designed to control and improve metabolic performance of these cells for the production of biological medicines. focusing on combinatorial gene editing, the consortium aims to generate robust phenotypes, which will not only enhance understanding of the CHO expression platform, but will ultimately lead to successful industrial translation. The project is designed to decrease the risk associated with the introduction of high levels of innovation in cell line engineering, while establishing a platform that can be made broadly accessible across the biopharmaceutical industry, in the UK and beyond. Horizon's gene editing platform will be used to manipulate pathways identified and subsequently tested by Manchester University to generate proof of concept. The performance of novel genotypes will be assessed in fermentors and scaled-up to 'manufacture-ready' processes at the CPI and its National Biologics Manufacturing Centre (NBMC) business unit, to ensure that project outputs are translatable into the manufacturing setting and outcomes are widely disseminated. Brian Burke, Business Development Director, Horizon, commented: "Cell line development through targeted gene editing will be critical in delivering the next generation of biological medicines. This funding award from Innovate UK will enable the development of an engineered CHO cell line toolkit that will drive new bioprocessing solutions beyond the term of the project, giving the bioprocessing community a foundation upon which further improvements in cell line systems can be built." Jonathan RF Robinson, Head of Business Development, NBMC: "CPI Biologics has been established to help companies develop innovative process and analytical technologies to enable the cost effective manufacture of novel therapeutic products. We see this project as a key enabler in meeting the current and future needs of the biologics industry and are delighted to be collaborating with Horizon and Prof. Alan Dickson." Prof. Alan Dickson, University of Manchester, said: "Our research focuses on increased molecular understanding of industrially-relevant mammalian cell expression systems and how such information can be used to enhance the commercial viability of bioprocessing. Partnering with Horizon and the CPI enables us to take this research to the next stage, with the aim of improving bioprocesses for application in industry. We are excited to see where it will lead." ENDS Notes to
KestleMill
12 Jan 2015
SP I think they are a great company and I am really interested in them but the SP is too high for me considering the amount of revenue they make (not much) and that they have pointed at future milestone payments from drug companies, but who's to say if these payments will ever be made? Looking at the recent jump to >£2 clearly others see it differently!
KayCatso
05 Dec 2014
Research report HL Hargreaves Lansdown recommended this share in a Biotech report published 4 Dec 2014 together with Abenza and Dechra Pharma. 20 dMA is crossing 50 dMA so could be a good time to buy. Not invested yet. My AIM choices have not been great and I tend to stick with FTSE350 shares.Will watch for a while and then decide. Good luck to all.Kay
